Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference22 articles.
1. Blay JY, Coindre JM, Ducimetiere F, Ray-Coquard I (2016) The value of research collaborations and consortia in rare cancers. Lancet Oncol 17(2):e62–e69.
https://doi.org/10.1016/s1470-2045(15)00388-5
2. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R (2011) Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 47(17):2493–2511.
https://doi.org/10.1016/j.ejca.2011.08.008
3. Heemstra HE, van Weely S, Buller HA, Leufkens HG, de Vrueh RL (2009) Translation of rare disease research into orphan drug development: disease matters. Drug Discov Today 14(23–24):1166–1173.
https://doi.org/10.1016/j.drudis.2009.09.008
4. Ministry of Health, Labour and Welfare (2015) Overview of orphan drug/medical device designation system. (in Japanese)
http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000068484.html
Accessed 06 Feb 2018
5. Maeda K, Kaneko M, Narukawa M, Arato T (2017) Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs. Orphanet J Rare Dis 12(1):143.
https://doi.org/10.1186/s13023-017-0690-5
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献